Follow the HLB파나진 stock price and the full directors' dealings record of the company, a listed equity based in South Korea. Shares are quoted on the KR market, under the oversight of DART (FSS). Operating in the Health Care sector, HLB파나진 has recorded 56 insider filings. Market capitalisation: €49.4bn. The latest transaction was reported on 16 July 2026 (Purchase). Among the most active insiders: HLB. Every trade is openly available.
51
Insider Decl.
n/a
Thresholds
€5m
32 ops.
Buy Volume
€4m
6 ops.
Sell Volume
15Σ signal
Buys €5m€4m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 22,808 of 29,056 companies
31.8
score / 100
Value
21
Quality
43
FCF yld-5.0%
Earn yld-6.1%
EV/EBITDA·
ROE·
Gross mgn60%
Net mgn-21%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
HLB파나진 is a healthcare and pharmaceutical company listed on the XKRX market. It specializes in the development of innovative treatments and therapeutic solutions.